Previous close | 781.10 |
Open | 774.76 |
Bid | 773.00 x 1200 |
Ask | 775.50 x 1100 |
Day's range | 768.25 - 782.60 |
52-week range | 419.80 - 800.78 |
Volume | |
Avg. volume | 3,116,267 |
Market cap | 738.227B |
Beta (5Y monthly) | 0.37 |
PE ratio (TTM) | 114.90 |
EPS (TTM) | 6.76 |
Earnings date | 30 Apr 2024 |
Forward dividend & yield | 5.20 (0.67%) |
Ex-dividend date | 14 Feb 2024 |
1y target est | 838.74 |
The Danish pharmaceutical giant, which became Europe’s most valuable company last year, said Wegovy sales jumped 106% in the first quarter.
Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected first-quarter profits as the Danish drugmaker races to boost output of its Wegovy weight-loss drug and fend off competition from rival Eli Lilly. Jyske Bank said the beat and upgrade were driven by a one-off U.S. sales adjustment, while underlying growth was a bit weaker than expected. Novo is currently the most valuable company in Europe by market capitalisation, worth some 540.4 billion euro ($576.44 billion) before Thursday's earnings, on the back of Wegovy's popularity.
Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected first-quarter profits as the Danish drugmaker races to boost output of its Wegovy weight-loss drug and fend off competition from rival Eli Lilly. Novo is currently the most valuable company in Europe by market capitalisation, worth some 540.4 billion euro ($576.44 billion) before Thursday's earnings, on the back of Wegovy's popularity.